Skip to main content
37°
Clear
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
Classifieds
Place ad
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Adagene Inc ADR
(NQ:
ADAG
)
2.730
UNCHANGED
Streaming Delayed Price
Updated: 3:59 PM EDT, Apr 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
-
Bid (Size)
2.650 (3)
Ask (Size)
2.730 (6)
Prev. Close
2.730
Today's Range
2.730 - 2.730
52wk Range
1.100 - 4.380
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
12 Health Care Stocks Moving In Monday's Intraday Session
April 01, 2024
Via
Benzinga
Adagene Reports Full Year 2023 Financial Results and Provides Corporate Update
March 29, 2024
From
Adagene Inc.
Via
GlobeNewswire
Performance
YTD
+39.29%
+39.29%
1 Month
+6.64%
+6.64%
3 Month
-9.00%
-9.00%
6 Month
+89.58%
+89.58%
1 Year
+96.40%
+96.40%
More News
Read More
Adagene Appoints Heinz-Josef Lenz, M.D., FACP to Scientific and Strategic Advisory Board
March 07, 2024
From
Adagene Inc.
Via
GlobeNewswire
Adagene to Present at the Leerink Partners Global Biopharma Conference 2024
February 27, 2024
From
Adagene Inc.
Via
GlobeNewswire
How Is The Market Feeling About Adagene?
January 18, 2024
Via
Benzinga
Adagene Announces Progress and Expansion of Clinical Collaboration Program for Masked, Anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with KEYTRUDA® (pembrolizumab) to Demonstrate Further Efficacy in Patients with Metastatic
February 09, 2024
From
Adagene Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Thursday's After-Market Session
February 01, 2024
Via
Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
January 22, 2024
Via
Benzinga
Week in Review: Lee’s Pharma Signs $138 Million Agreement For China Rights To Heart Failure Therapy
January 20, 2024
Via
Talk Markets
Why TransCode Therapeutics Shares Are Trading Lower By Over 24%? Here Are Other Stocks Moving In Friday's Mid-Day Session
January 19, 2024
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
January 19, 2024
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
January 18, 2024
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
January 17, 2024
Via
Benzinga
Why Airspan Networks Shares Are Trading Higher By Over 380%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
January 17, 2024
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
January 17, 2024
Via
Benzinga
Why Is Cancer Focused Adagene Stock Plummeting Today?
January 17, 2024
Via
Benzinga
Why DatChat Shares Are Trading Lower By Around 33%; Here Are 20 Stocks Moving Premarket
January 17, 2024
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
January 17, 2024
Via
InvestorPlace
Adagene Presents Interim Results Reinforcing Best-in-Class Profile of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)
January 16, 2024
From
Adagene Inc.
Via
GlobeNewswire
Adagene To Present Interim Results of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in MSS CRC at ASCO-GI Symposium
January 04, 2024
From
Adagene Inc.
Via
GlobeNewswire
Adagene Presents Data Demonstrating the Best-in-Class Therapeutic Index for Masked Anti-CTLA-4 SAFEbody® ADG126 at SITC 2023
November 03, 2023
From
Adagene Inc.
Via
GlobeNewswire
Adagene Announces Poster Presentation on Optimal Dose Selection for Masked Anti-CTLA-4 SAFEbody® ADG126 at Upcoming Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
October 12, 2023
From
Adagene Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Friday's Intraday Session
October 06, 2023
Via
Benzinga
Adagene to Present at Investor and Scientific Conferences in September
September 07, 2023
From
Adagene Inc.
Via
GlobeNewswire
Why Getty Images Holdings Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
October 03, 2023
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.